137 related articles for article (PubMed ID: 9001836)
21. Mibefradil, a pharmacologically distinct calcium antagonist.
Ernst ME; Kelly MW
Pharmacotherapy; 1998; 18(3):463-85. PubMed ID: 9620098
[TBL] [Abstract][Full Text] [Related]
22. Long-term antianginal and antiischemic effects of mibefradil, the novel T-type calcium channel blocker: a multicenter, double-blind, placebo-controlled, randomized comparison with sustained-release diltiazem.
Davies GJ; Kobrin I; Caspi A; Reisin LH; de Albuquerque DC; Armagnijan D; Coelho OR; Schneeweiss A
Am Heart J; 1997 Aug; 134(2 Pt 1):220-8. PubMed ID: 9313601
[TBL] [Abstract][Full Text] [Related]
23. Effect of mibefradil on left ventricular diastolic function in patients with congestive heart failure.
Muntinga HJ; van der Vring JA; Niemeyer MG; van den Berg F; Knol HR; Bernink PJ; van der Wall EE; Blanksma PK; Lie KI
J Cardiovasc Pharmacol; 1996 May; 27(5):652-6. PubMed ID: 8859934
[TBL] [Abstract][Full Text] [Related]
24. Mibefradil, a T-channel-selective calcium antagonist: clinical trials in hypertension.
Oparil S
Am J Hypertens; 1998 Apr; 11(4 Pt 3):88S-94S. PubMed ID: 9607372
[TBL] [Abstract][Full Text] [Related]
25. A comparison of the effects of mibefradil and atenolol on regression of left ventricular hypertrophy in hypertensive patients.
Höglund C; Cifkova R; Mimran A; Tenczer J; Watt A; Wilkins MR; Lindberg E
Cardiology; 1998 May; 89(4):263-70. PubMed ID: 9643273
[TBL] [Abstract][Full Text] [Related]
26. Mibefradil, a T-type channel-selective calcium antagonist: clinical trials in chronic stable angina pectoris.
Massie BM
Am J Hypertens; 1998 Apr; 11(4 Pt 3):95S-102S. PubMed ID: 9607373
[TBL] [Abstract][Full Text] [Related]
27. Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocking agent mibefradil in patients with varying degrees of left ventricular systolic dysfunction.
Rousseau MF; Hayashida W; van Eyll C; Hess OM; Benedict CR; Ahn S; Chapelle F; Kobrin I; Pouleur H
J Am Coll Cardiol; 1996 Oct; 28(4):972-9. PubMed ID: 8837576
[TBL] [Abstract][Full Text] [Related]
28. Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: the MACH-1 study. Mortality Assessment in Congestive Heart Failure Trial.
Levine TB; Bernink PJ; Caspi A; Elkayam U; Geltman EM; Greenberg B; McKenna WJ; Ghali JK; Giles TD; Marmor A; Reisin LH; Ammon S; Lindberg E
Circulation; 2000 Feb; 101(7):758-64. PubMed ID: 10683349
[TBL] [Abstract][Full Text] [Related]
29. Combination of calcium channel blockers and beta-adrenoceptor blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. Netherlands Working Group on Cardiovascular Research (WCN).
Van Der Vring JA; Daniëls MC; Holwerda NJ; Withagen PJ; Schelling A; Cleophas TJ; Hendriks MG
Br J Clin Pharmacol; 1999 May; 47(5):493-8. PubMed ID: 10336572
[TBL] [Abstract][Full Text] [Related]
30. Mibefradil: a new class of calcium-channel antagonists.
Billups SJ; Carter BL
Ann Pharmacother; 1998 Jun; 32(6):659-71. PubMed ID: 9640486
[TBL] [Abstract][Full Text] [Related]
31. Hemolysis on intravenous administration of a new calcium antagonist.
Kleinbloesem CH; Siepmann M; Kirch W
J Cardiovasc Pharmacol; 1995 Jun; 25(6):855-8. PubMed ID: 7564328
[TBL] [Abstract][Full Text] [Related]
32. The acute effects of intravenously administered mibefradil, a new calcium antagonist, on the electrophysiologic characteristics of the human heart.
Rosenquist M; Brembilla-Perrot B; Meinertz T; Neugebauer A; Crijns HJ; Smeets JL; van der Vring JA; Fromer M; Kobrin I
Eur J Clin Pharmacol; 1997; 52(1):7-12. PubMed ID: 9143860
[TBL] [Abstract][Full Text] [Related]
33. The design of the Mortality Assessment in Congestive Heart Failure Trial (MACH-1, mibefradil).
Levine TB
Clin Cardiol; 1997 Apr; 20(4):320-6. PubMed ID: 9098588
[TBL] [Abstract][Full Text] [Related]
34. The efficacy and safety of mibefradil in subgroups of patients with chronic stable angina pectoris.
Charlon V; Kobrin I
Int J Clin Pract; 1998 Jun; 52(4):257-64. PubMed ID: 9744152
[TBL] [Abstract][Full Text] [Related]
35. Comparative antihypertensive effectiveness of once-daily mibefradil and diltiazem CD. Mibefradil Hypertension Study Group.
Bittar N
Clin Ther; 1997; 19(5):954-62. PubMed ID: 9385483
[TBL] [Abstract][Full Text] [Related]
36. Mibefradil: a selective T-type calcium antagonist.
Massie BM
Am J Cardiol; 1997 Nov; 80(9A):23I-32I. PubMed ID: 9375939
[TBL] [Abstract][Full Text] [Related]
37. Mibefradil (posicor).
Giles TD
Compr Ther; 1997 Nov; 23(11):761-3. PubMed ID: 9360806
[No Abstract] [Full Text] [Related]
38. Potential cardioprotective effect of mibefradil in the long-term treatment of hypertension.
Waeber B
Cardiology; 1998; 89 Suppl 1():16-22. PubMed ID: 9570425
[TBL] [Abstract][Full Text] [Related]
39. The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension.
Lacourcière Y; Poirier L; Lefebvre J; Archambault F; Dalle Ave S; Ward C; Lindberg E
Am J Hypertens; 1997 Feb; 10(2):189-96. PubMed ID: 9037327
[TBL] [Abstract][Full Text] [Related]
40. Cytosolic calcium and lymphoproliferative response during calcium antagonism in men.
Lijnen P; Fagard R; Petrov V
Eur J Clin Pharmacol; 1999 Feb; 54(12):911-5. PubMed ID: 10192750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
